⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LTRN News
Lantern Pharma Inc. Common Stock
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
AVBP
SMMT
MRUS
MRK
GNPX
CGEM
ABBV
BMY
BDTX
LTRN
PFE
JNJ
LLY
Lantern Pharma to Present at the 7 th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
businesswire.com
LTRN
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
businesswire.com
LTRN
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
accessnewswire.com
SNYR
DVLT
NTHI
LTRN
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
businesswire.com
LTRN
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
accessnewswire.com
LTRN
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows
accessnewswire.com
LTRN
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
businesswire.com
LTRN
Lantern Pharma Presents LP-284 Clinical Data at 25 th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
businesswire.com
LTRN
LTRN
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
businesswire.com
LTRN
LTRN